Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of the types of candidate reference samples for quality control of human epidermal growth factor receptor 2 status detection

Published:2016-09-10 Issue:1 Volume:11 Page:
ISSN:1746-1596
Container-title:Diagnostic Pathology
language:en
Short-container-title:Diagn Pathol

Author:

Li Yulong,Zhang Rui,Han Yanxi,Lu Tian,Ding Jiansheng,Zhang Kuo,Lin Guigao,Xie Jiehong,Li Jinming

Funder

the Special Fund for Health Scientific Research in the Public Interest from National Population and Family Planning Commission of the PR China

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13000-016-0537-8.pdf

Reference24 articles.

1. Liu W, Xu J, Liu Y, Yu X, Tang X, Wang Z, et al. Anthocyanins potentiate the activity of trastuzumab in human epidermal growth factor receptor 2-positive breast cancer cells in vitro and in vivo. Mol Med Rep. 2014;10(4):1921–6. doi: 10.3892/mmr.2014.2414 .

2. Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, et al. Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol. 2015;68(2):93–9. doi: 10.1136/jclinpath-2014-202571 .

3. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236–44. doi: 10.1016/S1470-2045(11)70033-X .

4. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–84. doi: 10.1016/S0140-6736(09)61964-4 .

5. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379(9816):633–40. doi: 10.1016/S0140-6736(11)61847-3 .

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative comparison of immunohistochemical HER2‐low detection in an interlaboratory study;Histopathology;2024-07-29

2. External quality assessment for the molecular detection of microsatellite instability in China, 2021-2022;Expert Review of Molecular Diagnostics;2023-09-12

3. Lentiviral vector–based xenograft tumors as candidate reference materials for detection of HER2-low breast cancer;Frontiers in Oncology;2022-08-16

4. Detection of Epstein-Barr virus encoded RNA in fixed cells and tissues using CRISPR/Cas-mediated RCasFISH;Analytical Biochemistry;2021-07

5. Development of novel quality control material based on CRISPR/Cas9 editing and xenografts for MLH1 protein deficiency testing;Journal of Clinical Laboratory Analysis;2021-04-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3